Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
Esperion (NASDAQ: ESPR) has announced an upcoming R&D Day scheduled for April 24, 2025, at 9:00 a.m. ET in New York City. The event will showcase the company's research developments in ATP citrate lyase (ACLY) biology and its therapeutic applications for various life-threatening conditions.
The presentation will focus on how ACLY inhibitors could treat rare and chronic liver and kidney diseases. Esperion plans to reveal a new indication and introduce their lead candidate's development pathway. The event will feature key opinion leaders including Dr. Christos S. Mantzoros from Harvard Medical School and Dr. David E. Cohen from Brigham and Women's Hospital.
A live webcast will be available with pre-registration required on Esperion's website Investor section, with replay available for approximately 90 days after the event. In-person attendance requires advanced registration.
Esperion (NASDAQ: ESPR) ha annunciato una giornata di ricerca e sviluppo programmata per il 24 aprile 2025, alle 9:00 ET a New York City. L'evento metterà in mostra gli sviluppi di ricerca dell'azienda nella biologia dell'ATP citrato liasi (ACLY) e le sue applicazioni terapeutiche per varie condizioni potenzialmente letali.
La presentazione si concentrerà su come gli inibitori di ACLY potrebbero trattare malattie epatiche e renali rare e croniche. Esperion prevede di rivelare una nuova indicazione e di presentare il percorso di sviluppo del loro candidato principale. L'evento vedrà la partecipazione di leader di pensiero chiave, tra cui Dr. Christos S. Mantzoros della Harvard Medical School e Dr. David E. Cohen del Brigham and Women's Hospital.
Una diretta in streaming sarà disponibile con registrazione anticipata richiesta nella sezione Investitori del sito web di Esperion, con la possibilità di rivedere l'evento per circa 90 giorni dopo. La partecipazione di persona richiede una registrazione anticipata.
Esperion (NASDAQ: ESPR) ha anunciado un próximo Día de I+D programado para el 24 de abril de 2025, a las 9:00 a.m. ET en la ciudad de Nueva York. El evento mostrará los desarrollos de investigación de la compañía en biología de la ATP citrato liasa (ACLY) y sus aplicaciones terapéuticas para diversas condiciones potencialmente mortales.
La presentación se centrará en cómo los inhibidores de ACLY podrían tratar enfermedades hepáticas y renales raras y crónicas. Esperion planea revelar una nueva indicación e introducir la vía de desarrollo de su candidato principal. El evento contará con líderes de opinión clave, incluidos Dr. Christos S. Mantzoros de la Harvard Medical School y Dr. David E. Cohen del Brigham and Women's Hospital.
Se dispondrá de una transmisión en vivo con registro previo requerido en la sección de Inversores del sitio web de Esperion, con repetición disponible durante aproximadamente 90 días después del evento. La asistencia en persona requiere registro anticipado.
Esperion (NASDAQ: ESPR)는 2025년 4월 24일 오전 9시(동부 표준시)에 뉴욕시에서 예정된 R&D 데이를 발표했습니다. 이 이벤트는 ATP 시트르산 리아제 (ACLY) 생물학에 대한 회사의 연구 개발과 다양한 생명을 위협하는 질병에 대한 치료 응용을 선보일 것입니다.
발표는 ACLY 억제제가 희귀하고 만성적인 간 및 신장 질환을 치료할 수 있는 방법에 초점을 맞출 것입니다. Esperion은 새로운 적응증을 공개하고 주요 후보의 개발 경로를 소개할 계획입니다. 이 이벤트에는 Dr. Christos S. Mantzoros 하버드 의대와 Dr. David E. Cohen 브리검 여성병원의 주요 의견 리더들이 참여할 것입니다.
라이브 웹캐스트는 사전 등록이 필요하며 Esperion 웹사이트의 투자자 섹션에서 제공되며, 이벤트 후 약 90일 동안 다시 볼 수 있습니다. 대면 참석은 사전 등록이 필요합니다.
Esperion (NASDAQ: ESPR) a annoncé une journée de R&D prévue pour le 24 avril 2025 à 9h00 ET à New York. L'événement mettra en avant les développements de recherche de l'entreprise dans la biologie de l'ATP citrate lyase (ACLY) et ses applications thérapeutiques pour diverses conditions potentiellement mortelles.
La présentation se concentrera sur la manière dont les inhibiteurs d'ACLY pourraient traiter des maladies hépatiques et rénales rares et chroniques. Esperion prévoit de révéler une nouvelle indication et d'introduire le parcours de développement de leur candidat principal. L'événement mettra en vedette des leaders d'opinion clés, notamment Dr. Christos S. Mantzoros de la Harvard Medical School et Dr. David E. Cohen du Brigham and Women's Hospital.
Une diffusion en direct sera disponible, avec une préinscription requise dans la section Investisseurs du site web d'Esperion, et un replay sera disponible pendant environ 90 jours après l'événement. La participation en personne nécessite une inscription préalable.
Esperion (NASDAQ: ESPR) hat einen bevorstehenden F&E-Tag angekündigt, der für den 24. April 2025 um 9:00 Uhr ET in New York City geplant ist. Die Veranstaltung wird die Forschungsentwicklungen des Unternehmens in der Biologie der ATP-Citrat-Lyase (ACLY) und deren therapeutische Anwendungen für verschiedene lebensbedrohliche Erkrankungen präsentieren.
Die Präsentation wird sich darauf konzentrieren, wie ACLY-Inhibitoren seltene und chronische Leber- und Nierenerkrankungen behandeln könnten. Esperion plant, eine neue Indikation bekannt zu geben und den Entwicklungsweg ihres Hauptkandidaten vorzustellen. Die Veranstaltung wird wichtige Meinungsführer umfassen, darunter Dr. Christos S. Mantzoros von der Harvard Medical School und Dr. David E. Cohen vom Brigham and Women's Hospital.
Ein Live-Stream wird verfügbar sein, wobei eine vorherige Registrierung auf der Investoren-Seite der Esperion-Website erforderlich ist, und eine Wiederholung wird etwa 90 Tage nach der Veranstaltung verfügbar sein. Die Teilnahme vor Ort erfordert eine frühzeitige Registrierung.
- None.
- None.
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases
ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion’s research and development strategy.
Discussions will highlight Esperion’s advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indication and introduce the lead candidate selected for further development and its planned pathway to approval.
“We are excited to host this R&D Day to share our growing body of scientific evidence that support the therapeutic importance of and promise for targeting the cellular enzyme ACLY, which when dysregulated drives many diseases, including liver and kidney diseases,” said Sheldon Koenig, President and CEO of Esperion. “Allosteric ACLY inhibition is a novel approach to targeting this key enzyme, as abnormalities of ACLY are associated with several diseases effecting multiple cell types. We look forward to advancing our first product candidate from our next-generation ACLY inhibitor discovery program toward an Investigational New Drug Application in order to establish in humans what we have shown in robust pre-clinical work.”
Featured key opinion leaders will be:
- Christos S. Mantzoros, M.D., DSc, Ph.D. h.c. mult., Professor of Medicine at Harvard Medical School; and
- David E. Cohen, M.D., Ph.D., Chief, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital
A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast on the Investor section of the Esperion website. The archived replay will be available approximately two hours after completion of the event and will be archived on the Company's website for approximately 90 days. Please note advanced registration is required for in-person attendance.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When and where is Esperion's (ESPR) R&D Day taking place?
What therapeutic areas will ESPR's R&D Day presentation focus on?
Who are the key opinion leaders presenting at Esperion's 2025 R&D Day?
How can investors access Esperion's R&D Day presentation?
What is the significance of ACLY inhibition in Esperion's research pipeline?
